Molecular Templates Inc Quick Ratio (MTEM) starting from the second quarter 2024 to second quarter 2023, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Molecular Templates Inc   (NASDAQ: MTEM)

Molecular Templates Inc 's Quick Ratio

MTEM's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Molecular Templates Inc 's Cash & cash equivalent grew by 42.45 % in the Q2 2024 sequentially, while Current Liabilities decreased, this led to improvement in Molecular Templates Inc 's Quick Ratio to 1.26, Quick Ratio remained below Molecular Templates Inc average.

Within Major Pharmaceutical Preparations industry 366 other companies have achieved higher Quick Ratio than Molecular Templates Inc in second quarter 2024. While Quick Ratio total ranking in the second quarter 2024 has deteriorated compared to the prior quarter from 1153 to 1817.

Explain Quick Ratio?
How much Cash & cash equivalents MTEM´s has?
What are MTEM´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

MTEM Quick Ratio (Jun 30 2024)
Q2		 (Mar 31 2024)
Q1		 (Dec 31 2023)
Q4		 (Sep 30 2023)
Q3		 (Jun 30 2023)
Q2
Y / Y Current Liabilities Change -71.49 % -71.3 % -69.66 % -57.17 % -41.91 %
Y / Y Cash & cash equivalent Change 95.01 % -83.73 % -81.12 % -80.1 % -95.26 %
Quick Ratio MRQ 1.26 0.79 0.67 0.73 0.18
MTEM's Total Ranking # 1817 # 1153 # 1498 # 1493 # 3353
Seq. Current Liabilities Change -10.5 % -50.46 % -19.48 % -20.14 % -9.91 %
Seq. Cash & cash equivalent Change 42.45 % -41.17 % -27.12 % 219.29 % -88.12 %



Quick Ratio second quarter 2024 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 367
Healthcare Sector # 677
Overall Market # 1817


Quick Ratio Statistics
High Average Low
17.56 4.51 0.18
(Jun 30 2011)   (Jun 30 2023)




Financial Statements
Molecular Templates Inc 's Current Liabilities $ 8 Millions Visit MTEM's Balance sheet
Molecular Templates Inc 's Cash & cash equivalent $ 10 Millions Visit MTEM's Balance sheet
Source of MTEM's Sales Visit MTEM's Sales by Geography


Cumulative Molecular Templates Inc 's Quick Ratio

MTEM's Quick Ratio for the trailling 12 Months

MTEM Quick Ratio

 (Jun 30 2024)
12 Months		 (Mar 31 2024)
12 Months		 (Dec 31 2023)
12 Months		 (Sep 30 2023)
12 Months		 (Jun 30 2023)
12 Months
Y / Y Current Liabilities TTM Growth -66.43 % -59.5 % -51.85 % -28.07 % -11.5 %
Y / Y Cash & cash equivalent TTM Growth -76.61 % -86.37 % -79.98 % -72.65 % -65.44 %
Quick Ratio TTM 0.79 0.53 0.77 0.91 1.14
Total Ranking TTM # 4091 # 932 # 2677 # 2812 # 3353
Seq. Current Liabilities TTM Growth -25.9 % -22.28 % -29.36 % -17.49 % -10.59 %
Seq. Cash & cash equivalent TTM Growth 12.04 % -47.18 % -40.11 % -34.01 % -34.71 %

Quick ratio ranking by company, industry and sector >> Back to MTEM Financial Strength Comparisons >> Go to Compare MTEM Quick Ratio to its Competitors

On the trailing twelve months basis MTEM Cash & cash equivalent soared by 95.01 % in Q2 2024 year on year, while Current Liabilities fell to $8 millions, this led to increase in in Molecular Templates Inc 's Quick Ratio to 0.79, Quick Ratio remained below MTEM average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 494 other companies have achieved higher Quick Ratio than Molecular Templates Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2024 from 932 to 4091.

Explain Quick Ratio?
How much Cash & cash equivalents MTEM´s has?
What are MTEM´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 495
Healthcare Sector # 1033
Within the Market # 4091


trailing twelve months Quick Ratio Statistics
High Average Low
6.99 3.11 0.53
(Jun 30 2017)   (Mar 31 2024)




Companies with similar Quick Ratio in the quarter ending Jun 30 2024, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2024 MRQ Cash & cash equivalentJun 30 2024 MRQ Current Liabilities
Allakos Inc   3.43 $ 123.121  Millions$ 35.880  Millions
Regeneron Pharmaceuticals Inc   3.36 $ 9,809.000  Millions$ 2,922.600  Millions
Cartesian Therapeutics Inc   3.34 $ 87.227  Millions$ 26.115  Millions
Bridgebio Pharma Inc   3.33 $ 447.771  Millions$ 134.364  Millions
Nuvectis Pharma inc   3.32 $ 18.116  Millions$ 5.460  Millions
Maia Biotechnology Inc   3.30 $ 11.579  Millions$ 3.511  Millions
Can fite Biopharma Ltd   3.26 $ 7.785  Millions$ 2.391  Millions
Syros Pharmaceuticals Inc   3.22 $ 78.964  Millions$ 24.521  Millions
Uniqure N v   3.18 $ 287.877  Millions$ 90.643  Millions
Quoin Pharmaceuticals Ltd   3.17 $ 12.545  Millions$ 3.953  Millions
Trevena inc   3.14 $ 16.367  Millions$ 5.206  Millions
Blueprint Medicines Corporation  3.13 $ 763.602  Millions$ 243.803  Millions
Mannkind Corporation  3.10 $ 247.761  Millions$ 80.012  Millions
Phio Pharmaceuticals Corp  3.08 $ 4.698  Millions$ 1.523  Millions
Vincerx Pharma Inc   3.06 $ 16.319  Millions$ 5.332  Millions
Scpharmaceuticals Inc   3.02 $ 38.504  Millions$ 12.740  Millions
Gain Therapeutics inc  3.01 $ 16.936  Millions$ 5.626  Millions
Ardelyx inc   2.98 $ 185.961  Millions$ 62.436  Millions
Scynexis Inc   2.89 $ 73.038  Millions$ 25.233  Millions
Metavia Inc   2.88 $ 27.934  Millions$ 9.711  Millions
Gri Bio Inc   2.87 $ 6.353  Millions$ 2.216  Millions
Arcturus Therapeutics Holdings Inc   2.84 $ 260.329  Millions$ 91.717  Millions
Kala Bio inc   2.82 $ 54.197  Millions$ 19.190  Millions
Ultragenyx Pharmaceutical Inc   2.80 $ 763.821  Millions$ 272.866  Millions
Biohaven Ltd   2.80 $ 436.948  Millions$ 156.207  Millions
Optinose Inc   2.79 $ 91.358  Millions$ 32.700  Millions
Hookipa Pharma inc   2.77 $ 77.150  Millions$ 27.834  Millions
Verastem Inc   2.75 $ 83.371  Millions$ 30.347  Millions
Veru Inc   2.74 $ 29.151  Millions$ 10.620  Millions
Oncternal Therapeutics Inc   2.72 $ 21.429  Millions$ 7.870  Millions

Date modified: 2026-09-18T13:11:05+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.